Telix Pharmaceuticals Stock Fundamentals
| TLX Stock | 25.74 0.80 3.21% |
Telix Pharmaceuticals fundamentals help investors to digest information that contributes to Telix Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Telix Stock. The fundamental analysis module provides a way to measure Telix Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telix Pharmaceuticals stock.
At this time, Telix Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Total Revenue is likely to gain to about 521.5 M in 2024, despite the fact that Net Loss is likely to grow to (89 M). Telix | Select Account or Indicator |
Telix Pharmaceuticals Company Return On Equity Analysis
Telix Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Telix Pharmaceuticals Return On Equity | 0.2 |
Most of Telix Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telix Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Telix Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Telix Pharmaceuticals has a Return On Equity of 0.2049. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The return on equity for all Australia stocks is notably lower than that of the firm.
Telix Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Telix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Telix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Telix Pharmaceuticals competition to find correlations between indicators driving Telix Pharmaceuticals's intrinsic value. More Info.Telix Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.39 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Telix Pharmaceuticals is roughly 2.57 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telix Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Telix Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telix Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Telix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Telix Pharmaceuticals by comparing valuation metrics of similar companies.Telix Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Telix Fundamentals
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 8.25 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Shares Owned By Insiders | 41.42 % | ||||
| Shares Owned By Institutions | 17.91 % | ||||
| Price To Book | 20.66 X | ||||
| Price To Sales | 13.23 X | ||||
| Revenue | 496.66 M | ||||
| Gross Profit | 98.54 M | ||||
| EBITDA | 22.97 M | ||||
| Net Income | 5.21 M | ||||
| Total Debt | 17.45 M | ||||
| Book Value Per Share | 1.21 X | ||||
| Cash Flow From Operations | 23.88 M | ||||
| Earnings Per Share | 0.15 X | ||||
| Target Price | 25.62 | ||||
| Beta | 2.38 | ||||
| Market Capitalization | 8.55 B | ||||
| Total Asset | 398.3 M | ||||
| Retained Earnings | (263.67 M) | ||||
| Working Capital | 67.44 M | ||||
| Net Asset | 398.3 M |
About Telix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telix Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 11 M | 6.4 M | |
| Total Revenue | 496.7 M | 521.5 M | |
| Cost Of Revenue | 188.2 M | 197.6 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.